Expression of long-chain non-coding RNA-CECR7 and prognosis in gastric cancer

doi:10.3877/cma.j.issn.1674-0793.2020.06.006

Abstract

Abstract:

Objective

To investigate the expression of long non-coding RNA-CECR7 (lncRNA-CECR7) in gastric cancer and its relationship with prognosis.

Methods

Seventy-eight patients with gastric cancer admitted to the First Affiliated Hospital of Chengdu Medical College from May 2015 to May 2016 were studied. The relative expression of lncRNA-CECR7 in gastric cancer tissues and adjacent tissues was detected by quantitative real-time PCR (RT-PCR). The relationship between the expression of lncRNA-CECR7 and the clinicopathological parameters of patients were analyzed. Kaplan-Meier curve survival analysis and Cox regression analysis were used to analyze the factors affecting the 3-year survival rate.

Results

The expression level of lncRNA-CECR7 in gastric cancer tissues was higher than that in adjacent tissues (1.87±0.25 vs 1.05±0.13, t=25.701, P<0.001). The expression of lncRNA-CECR7 was correlated with tumor size, Borrmann typing, TNM stage, differentiation type and lymph node metastasis (P<0.05). The 3-year survival rate was 62.82%. Tumor size, TNM stage, lymph node metastasis and expression of lncRNA-CECR7 were independent factors affecting the prognosis of gastric cancer patients (P<0.05). The survival rate of low expression group of lncRNA-CECR7 was significantly higher than that of high expression group of lncRNA-CECR7 (77.14% vs 51.16%, χ2=5.576, P=0.018).

Conclusion

lncRNA-CECR7 is highly expressed in gastric cancer tissues, which is related to tumor size, Borrmann typing and TNM stage, and is a risk factor for 3-year survival of gastric patients.

Key words: Stomach neoplasms, Long non-coding RNA-CECR7, Prognosis

Min Peng, Yan Ren, Feng Yan, Yingxin Wu. Expression of long-chain non-coding RNA-CECR7 and prognosis in gastric cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2020, 14(06): 425-428.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2020.06.006

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2020/V14/I06/425

Figures/Tables 4

References 11

[1]	刘沈林. 胃癌临床治疗的实践与思考[J]. 中国中西医结合杂志, 2019, 39(1): 13-14.
[2]	Reichelt-Wurm S, Wirtz T, Chittka D, et al. Glomerular expression pattern of long non-coding RNAs in the type 2 diabetes mellitus BTBR mouse model[J]. Sci Rep, 2019, 9(1): 9765.
[3]	王向辉, 黄江平, 崔丰和, 等. 长链非编码RNA-CECR7抑制食管癌细胞增殖和凋亡的机制研究[J]. 国际消化病杂志, 2018, 38(4): 242-246.
[4]	Hosokawa Y, Kinoshita T, Konishi M, et al. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan[J]. Ann Surg Oncol, 2012, 19(2): 677-683.
[5]	Takeshi S, Daniel GC, Hyung HK, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association Staging Project[J]. Gastric Cancer, 2017, 20(2): 217-225.
[6]	Tam C, Wong JH, Tsui S, et al. LncRNAs with miRNAs in regulation of gastric, liver, and colorectal cancers: updates in recent years[J]. Appl Microbiol Biotechnol, 2019, 103(12): 4649-4677.
[7]	Wei GH, Wang X. LncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2017, 21(17): 3850-3856.
[8]	Yao K, Wang Q, Jia J, et al. A competing endogenous RNA network identifies novel mRNA, miRNA and lncRNA markers for the prognosis of diabetic pancreatic cancer[J]. Tumour Biol, 2017, 39(6): 1010428317707882.
[9]	侯守超, 汪丹丹, 郑蔚, 等. 胃癌辅助化疗患者症状群的纵向研究[J]. 现代预防医学, 2018, 45(18): 3434-3438.
[10]	Sun B, Dang Y, Zhang F, et al. Long non-coding RNA RP1-163G9.1 is downregulated in gastric adenocarcinoma and is associated with a poor prognosis[J]. Oncol Rep, 2019, 41(6): 3575-3585.
[11]	Zhang J, Fan D, Jian Z, et al. Cancer specific long noncoding RNAs show differential expression patterns and competing endogenous RNA potential in hepatocellular carcinoma[J]. PLoS One, 2015, 10(10): e0141042.

临床指标		例数	高表达(43例)	低表达(35例)	χ²值	P值
性别					0.333	0.564
	男	44	23	21
	女	34	20	14
年龄(岁)					0.047	0.829
	>60	30	17	13
	≤60	48	26	22
肿瘤部位					0.076	0.963
	胃窦	28	15	13
	胃体	13	7	6
	胃底贲门	37	21	16
肿瘤大小(cm)					5.761	0.016
	<5	59	28	31
	≥5	19	15	4
Borrmann分型					4.908	0.027
	Ⅰ~Ⅱ	45	20	25
	Ⅲ~Ⅳ	33	23	10
TNM分期					4.653	0.031
	Ⅰ~Ⅱ	55	26	29
	Ⅲ~Ⅳ	23	17	6
分化类型					11.666	0.003
	低	16	12	4
	中	23	17	6
	高	39	14	25
淋巴结转移					5.534	0.019
	是	24	18	6
	否	54	25	29
组织学分型					0.602	0.740
	鳞癌	6	4	2
	腺癌	64	34	30
	腺鳞癌	8	5	3

临床指标		例数	高表达(43例)	低表达(35例)	χ²值	P值
性别					0.333	0.564
	男	44	23	21
	女	34	20	14
年龄(岁)					0.047	0.829
	>60	30	17	13
	≤60	48	26	22
肿瘤部位					0.076	0.963
	胃窦	28	15	13
	胃体	13	7	6
	胃底贲门	37	21	16
肿瘤大小(cm)					5.761	0.016
	<5	59	28	31
	≥5	19	15	4
Borrmann分型					4.908	0.027
	Ⅰ~Ⅱ	45	20	25
	Ⅲ~Ⅳ	33	23	10
TNM分期					4.653	0.031
	Ⅰ~Ⅱ	55	26	29
	Ⅲ~Ⅳ	23	17	6
分化类型					11.666	0.003
	低	16	12	4
	中	23	17	6
	高	39	14	25
淋巴结转移					5.534	0.019
	是	24	18	6
	否	54	25	29
组织学分型					0.602	0.740
	鳞癌	6	4	2
	腺癌	64	34	30
	腺鳞癌	8	5	3

临床指标		例数	3年生存(49例)	3年死亡(29例)	χ²值	P值
性别					0.033	0.855
	男	44	25	19
	女	34	24	10
年龄(岁)					0.005	0.941
	>60	30	19	11
	≤60	48	30	18
肿瘤部位					0.129	0.938
	胃窦	28	17	11
	胃体	13	8	5
	胃底贲门	37	24	13
肿瘤大小(cm)					1.116	0.291
	<5	59	39	20
	≥5	19	10	9
Borrmann分型					5.033	0.025
	Ⅰ、Ⅱ型	45	33	12
	Ⅲ、Ⅳ型	33	16	17
TNM分期					5.225	0.022
	Ⅰ、Ⅱ期	55	39	16
	Ⅲ、Ⅳ期	23	10	13
分化类型					11.875	0.003
	低	16	4	12
	中	23	13	10
	高	39	32	7
淋巴结转移					4.283	0.038
	是	24	11	13
	否	54	38	16
组织学分型					0.643	0.725
	鳞癌	6	4	2
	腺癌	64	39	25
	腺鳞癌	8	6	2

临床指标		例数	3年生存(49例)	3年死亡(29例)	χ²值	P值
性别					0.033	0.855
	男	44	25	19
	女	34	24	10
年龄(岁)					0.005	0.941
	>60	30	19	11
	≤60	48	30	18
肿瘤部位					0.129	0.938
	胃窦	28	17	11
	胃体	13	8	5
	胃底贲门	37	24	13
肿瘤大小(cm)					1.116	0.291
	<5	59	39	20
	≥5	19	10	9
Borrmann分型					5.033	0.025
	Ⅰ、Ⅱ型	45	33	12
	Ⅲ、Ⅳ型	33	16	17
TNM分期					5.225	0.022
	Ⅰ、Ⅱ期	55	39	16
	Ⅲ、Ⅳ期	23	10	13
分化类型					11.875	0.003
	低	16	4	12
	中	23	13	10
	高	39	32	7
淋巴结转移					4.283	0.038
	是	24	11	13
	否	54	38	16
组织学分型					0.643	0.725
	鳞癌	6	4	2
	腺癌	64	39	25
	腺鳞癌	8	6	2

变量	β	SE	Wald	P值	HR	95% CI
肿瘤大小	1.655	0.732	5.119	0.026	5.234	1.269~8.264
Borrmann分型	0.314	0.309	1.032	0.072	1.364	0.926~5.132
TNM分期	1.006	0.327	9.447	0.002	2.736	1.441~5.192
分化类型	-0.629	0.334	3.548	0.060	0.533	0.277~1.026
淋巴结转移	1.264	0.298	18.049	<0.001	3.541	1.976~6.345
lncRNA-CECR7	0.777	0.263	8.704	0.003	2.175	1.298~3.645

Please choose a citation manager

Content to export